Amedeo Smart

Free Medical Literature Service


 

Amedeo

Lung Cancer

  Free Subscription

18.08.2025

1 Am J Ind Med
3 Ann Surg Oncol
3 Ann Thorac Surg
5 BMC Cancer
2 Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Chest
1 Clin Cancer Res
1 Clin Lung Cancer
2 Eur J Cancer
1 J Cancer Res Clin Oncol
2 J Clin Oncol
2 JAMA Oncol
2 Lancet
17 Lung Cancer
1 Nat Genet
1 Oncogene
1 Oncol Rep
1 PLoS One



    Am J Ind Med

  1. CAREY RN, Reid A, de Klerk N, Cinquini P, et al
    Mortality and Cancer Incidence After Exposure to Blue Asbestos in Childhood: A Further 10 Years of Follow-Up.
    Am J Ind Med. 2025;68:772-783.
    >> Share


    Ann Surg Oncol

  2. XING Y, Zhou J, Yang Z, Dai Z, et al
    Visible Pleural Retraction is a Prognostic Marker in Early-Stage Non-Small Cell Lung Cancer: A Retrospective Cohort Study.
    Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-17946.
    >> Share

  3. UEDA D, Mimae T, Okada M
    Reply to: "Should Muscle Mass be Incorporated into Surgical Decision Making for Early-Stage Lung Cancer?", by Yan et al.
    Ann Surg Oncol. 2025 Aug 9. doi: 10.1245/s10434-025-18049.
    >> Share

  4. HUANG K, Li P, Wu Q, Tang X, et al
    Sleeve Lobectomy, Pulmonary Artery Plasty, and Superior Vena Cava Reconstruction for Locally Advanced Non-small Cell Lung Cancer: A Single-Center Retrospective Study.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-17652.
    >> Share


    Ann Thorac Surg

  5. GRIFFITH A, Pratt CG, Whitrock JN, Moore AN, et al
    Achieving Equitable Care for Racial Minority Patients with a Lung Cancer Screening Program.
    Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00749.
    >> Share

  6. EZENWANKWO E
    Securing CT Lung Cancer Screening Access: Implications of the Supreme Court's Ruling in Kennedy v. Braidwood.
    Ann Thorac Surg. 2025 Aug 12:S0003-4975(25)00755.
    >> Share

  7. ABDALLAT M, Leo RT, Sugarbaker EA, McAllister M, et al
    Segmentectomy vs Lobectomy for Occult N1 in Non-Small Cell Lung Cancer: Is Less Still More?
    Ann Thorac Surg. 2025 Aug 8:S0003-4975(25)00725.
    >> Share


    BMC Cancer

  8. JIANG Z, Zhao F, Li B, He J, et al
    Multidimensional comparative evaluation of first-line therapies for extensive-stage small cell lung cancer: a systematic review and network meta-analysis of clinical efficacy and safety profiles.
    BMC Cancer. 2025;25:1292.
    >> Share

  9. LOBINGER D, Taylor N, Messner V, Seier S, et al
    Circulating Hsp70: a tumor biomarker for lymph node metastases and early relapse in thoracic cancer.
    BMC Cancer. 2025;25:1297.
    >> Share

  10. LUAN X, Han X, Wang Z, Zhao L, et al
    Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic patterns.
    BMC Cancer. 2025;25:1287.
    >> Share

  11. LIN X, Liu S, Ding Y, Zhao J, et al
    Contrasting tracheal, bronchus, and lung cancer burdens and care quality: a comparative analysis of China and global trends.
    BMC Cancer. 2025;25:1298.
    >> Share

  12. JAPUNTICH SJ, Sacasa NG, Cameron S, Balletto B, et al
    Lung cancer screening experiences among patients with a smoking history and primary care providers: a qualitative study.
    BMC Cancer. 2025;25:1305.
    >> Share


    Cancer

  13. STUDTS JL, Carter-Bawa L, Hamann HA, Smith RA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Changing the lung cancer story: Addressing survivorship, stigma, and nihilism to facilitate transformation.
    Cancer. 2025;131:e35969.
    >> Share

  14. OLSON JMG, Knight JR, Copeland AM, Ohlander KA, et al
    The American Cancer Society National Lung Cancer Roundtable strategic plan: Addressing planning for lung cancer interventions at the state and local level through the creation of the National Lung Cancer Roundtable Planning Tool.
    Cancer. 2025;131:e35954.
    >> Share


    Cancer Epidemiol Biomarkers Prev

  15. PESTARINO L, Fortner RT, Nost TH, Fotopoulos I, et al
    Recommendations for validating omics prediction models: Insights from a lung cancer RNA biomarker study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    >> Share


    Chest

  16. MURGU S, Chen AC, Gilbert CR, Sterman DH, et al
    A Prospective, Multicenter Evaluation of Safety and Diagnostic Outcomes With Robotic-Assisted Bronchoscopy: Results of the Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung (TARGET) Trial.
    Chest. 2025;168:539-555.
    >> Share

  17. YE Y, An P
    Reassessing Communication Strategies in Lung Cancer Screening: Implications for Patient-Centered Outcomes.
    Chest. 2025;168:e55-e56.
    >> Share


    Clin Cancer Res

  18. CIARDULLO C, Tobalina L, Carr TH, Szekeres P, et al
    Early ctDNA dynamics inform first-line therapy in patients with extensive-stage small cell lung cancer.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-2011.
    >> Share


    Clin Lung Cancer

  19. TELLI TA, Tatli AM, Alan O, Keskin GY, et al
    Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
    Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00159.
    >> Share


    Eur J Cancer

  20. YAMAGUCHI K, Takao S, Kanaji N, Hirakawa T, et al
    The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
    Eur J Cancer. 2025;226:115606.
    >> Share

  21. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    >> Share


    J Cancer Res Clin Oncol

  22. WU X, Fang K, Huang W, Chen G, et al
    Combined small-cell lung cancer with adenocarcinoma: a rare case and literatures review.
    J Cancer Res Clin Oncol. 2025;151:230.
    >> Share


    J Clin Oncol

  23. GONDI V, Pugh SL, Mehta MP, Wefel JS, et al
    Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
    J Clin Oncol. 2025 Aug 11:JCO2500221. doi: 10.1200/JCO-25-00221.
    >> Share

  24. COOPER BT, Kondziolka D
    Modern Targeted Radiation in Patients With Brain Metastases From Small Cell Lung Cancer.
    J Clin Oncol. 2025 Aug 12:JCO2501259. doi: 10.1200/JCO-25-01259.
    >> Share


    JAMA Oncol

  25. ROLLE LD, Crane TE
    Methodological Concerns With Lung Cancer Screening Estimates-Reply.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2581.
    >> Share

  26. BURUS T, McAfee CR, Hull PC
    Methodological Concerns With Lung Cancer Screening Estimates.
    JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2584.
    >> Share


    Lancet

  27. SMIT EF, Dingemans AC
    Adagrasib for KRAS(G12C) mutated advanced non-small-cell lung cancer.
    Lancet. 2025;406:576-577.
    >> Share

  28. BARLESI F, Yao W, Duruisseaux M, Doucet L, et al
    Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
    Lancet. 2025;406:615-626.
    >> Share


    Lung Cancer

  29. CUMMINGS AL, Sussell J, Rosettie KL, Moustaid FE, et al
    A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.
    Lung Cancer. 2025;207:108701.
    >> Share

  30. YU Y, Pan Y, Zhou J, Mu S, et al
    Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.
    Lung Cancer. 2025;207:108710.
    >> Share

  31. ALI AS, Irfan M
    Second-hand smoke and survival in former smokers with lung cancer: time to act.
    Lung Cancer. 2025 Aug 11:108713. doi: 10.1016/j.lungcan.2025.108713.
    >> Share

  32. CHATURVEDI A, Som A
    Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in lung adenocarcinoma.
    Lung Cancer. 2025;206:108540.
    >> Share

  33. HUBERT J, Moldovanu D, van den Bosch I, de Nijs K, et al
    Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial.
    Lung Cancer. 2025;207:108686.
    >> Share

  34. LEE J, Kim M, Han HJ, Kim S, et al
    Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study.
    Lung Cancer. 2025;206:108682.
    >> Share

  35. PRONSATI N, Liu G, Bauer TM, Felip E, et al
    Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
    Lung Cancer. 2025;206:108662.
    >> Share

  36. FUJINO K, Suda K, Yoshikawa M, Shien K, et al
    Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
    Lung Cancer. 2025;206:108672.
    >> Share

  37. LU F, Lv C, Yang X, Zhuo M, et al
    Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
    Lung Cancer. 2025;206:108676.
    >> Share

  38. NIEDERMAIER B, Rolf E, Allgauer M, Klotz LV, et al
    Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma.
    Lung Cancer. 2025;206:108674.
    >> Share

  39. LYNCH GA, Symonds J, Morley A, Azubuike-Dyer E, et al
    Serum mesothelin as a response biomarker in pleural mesothelioma.
    Lung Cancer. 2025;206:108670.
    >> Share

  40. PANDEY A, Gomez E, Soto A, Jr MA, et al
    A novel murine carcinogen-induced model recapitulates the progression and heterogeneity of human lung adenocarcinoma.
    Lung Cancer. 2025;206:108581.
    >> Share

  41. DUMANE V, Runnels J, Flores R, Wolf A, et al
    Long term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma.
    Lung Cancer. 2025;206:108639.
    >> Share

  42. GAGNE A, Alessi JVM, Ricciuti B, Lamberti G, et al
    Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas.
    Lung Cancer. 2025;206:108644.
    >> Share

  43. MEDUSA PM, Carro N, Morgillo F, Guida GD, et al
    Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.
    Lung Cancer. 2025;206:108617.
    >> Share

  44. ZOLOV S, Chuikov S, Katkam SK, Chockley PJ, et al
    Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in lung adenocarcinoma.
    Lung Cancer. 2025;206:108643.
    >> Share

  45. LANGER S, Medenwald D, Vordermark D, Schuette W, et al
    Therapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic review.
    Lung Cancer. 2025;206:108640.
    >> Share


    Nat Genet

  46. KLOTZER KA, Abedini A, Li S, Balzer MS, et al
    Analysis of individual patient pathway coordination in a cross-species single-cell kidney atlas.
    Nat Genet. 2025;57:1922-1934.
    >> Share


    Oncogene

  47. LIU L, Chen S, Lei Y, Lin Z, et al
    REPS2 attenuates cancer stemness through inhibiting Wnt signaling by autophagy mediated degradation of beta-catenin.
    Oncogene. 2025;44:2942-2955.
    >> Share


    Oncol Rep

  48. LEI Y, Guo W, Chen B, Chen L, et al
    [Retracted] Tumor?released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non?small cell lung cancer.
    Oncol Rep. 2025;54:140.
    >> Share


    PLoS One

  49. ABDOLLAHI A, Favata M, Weber M, Roman V, et al
    The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
    PLoS One. 2025;20:e0327588.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016